Impact of the Timing of Initial Anamorelin Administration in Advanced Gastrointestinal Cancer With Cancer Cachexia
In Vivo · 2025
DOI: 10.21873/invivo.14137 ↗Kurz gefasst
Fachartikel in der Zeitschrift In Vivo, 2025. Verfasst von Daisuke Yoshida und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Beppu Medical Center, Oita, Japan alfadai@pearl.ocn.ne.jp. Hauptthemen laut MEDLINE: Cachexia, Gastrointestinal Neoplasms, Oligopeptides. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND/AIM: Cachexia is a multifactorial syndrome that adversely affects the prognosis of patients with gastrointestinal cancer. Although anamorelin has been shown to improve appetite and body weight, the optimal timing of its initiation remains unclear. This study evaluated the effects of the timing of anamorelin initiation on nutritional recovery and clinical outcomes in patients with gastrointestinal cancer cachexia. PATIENTS AND METHODS: We retrospectively reviewed 42 patients with gastric (n=17) or colorectal cancer (n=25) complicated by cachexia who received 100 mg of anamorelin once daily between August 2021 and December 2024. Changes in body weight, food intake, and nutritional status were assessed before and after anamorelin administration, and overall survival was analyzed according to the type of cancer. RESULTS: Initially, patients had experienced a mean body weight loss of 15.9±1.7% relative to the pre-diagnosis baseline. After four weeks, mean body weight increased by 2.9% (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Beppu Medical Center, Oita, Japan alfadai@pearl.ocn.ne.jp.
- Department of Surgery, Beppu Medical Center, Oita, Japan.
- Department of Gastroenterology, Beppu Medical Center, Oita, Japan.
Zitieren
APA
Yoshida, D., Ishimatsu, M., Nakashima, S., Nakano, K., Ishida, S., Orimoto, H., Miyagahara, T., Yada, K., Matsumoto, T., & Kawanaka, H. (2025). Impact of the Timing of Initial Anamorelin Administration in Advanced Gastrointestinal Cancer With Cancer Cachexia. In Vivo. https://doi.org/10.21873/invivo.14137
Vancouver
Yoshida D, Ishimatsu M, Nakashima S, Nakano K, Ishida S, Orimoto H, et al. Impact of the Timing of Initial Anamorelin Administration in Advanced Gastrointestinal Cancer With Cancer Cachexia. In Vivo. 2025. doi:10.21873/invivo.14137
BibTeX
@article{Yoshida2025,
author = {Yoshida, Daisuke and Ishimatsu, Makoto and Nakashima, Shuto and Nakano, Kouji and Ishida, Shunsuke and Orimoto, Hiroki and Miyagahara, Tsukasa and Yada, Kazuhiro and Matsumoto, Toshifumi and Kawanaka, Hirofumi},
title = {Impact of the Timing of Initial Anamorelin Administration in Advanced Gastrointestinal Cancer With Cancer Cachexia},
journal = {In Vivo},
year = {2025},
doi = {10.21873/invivo.14137}
}
EUVIMED